Carisoprodol Alternatives Compared
| Carisoprodol | Cyclobenzaprine | Tizanidine |
|
|---|
| Carisoprodol | Cyclobenzaprine | Tizanidine |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Carisoprodol is a muscle relaxant; however, its use is limited by its potential for dependence, sedative effects, and the length of time it lasts which means it requires dosing several times a day... View more |
Prescription only
Cyclobenzaprine is a muscle relaxant that may be used short-term to treat muscle spasms caused by musculoskeletal conditions, in addition to rest and physical therapy. Sedation is a common side... View more |
Prescription only
Tizanidine may be used to reduce muscle spasms but common side effects include sleepiness, a drop in blood pressure, and a dry mouth. The dosage of tizanidine should be tailored to each person and... View more |
Related suggestions Popular comparisons
|
|||||||||||||||||||||||
| More about Carisoprodol | More about Cyclobenzaprine | More about Tizanidine | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Carisoprodol has an average rating of 8.9 out of 10 from a total of 314 ratings on Drugs.com. 87% of reviewers reported a positive effect, while 7% reported a negative effect. |
Cyclobenzaprine has an average rating of 6.0 out of 10 from a total of 621 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 30% reported a negative effect. |
Tizanidine has an average rating of 6.2 out of 10 from a total of 385 ratings on Drugs.com. 49% of reviewers reported a positive effect, while 29% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Carisoprodol side effects |
View all Cyclobenzaprine side effects |
View all Tizanidine side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
Lower cost generic |
Lower cost generic |
Lower cost generic |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Carisoprodol prices |
View all Cyclobenzaprine prices |
View all Tizanidine prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Soma | Amrix, Comfort Pac with Cyclobenzaprine | Ontralfy, Zanaflex | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
8 hours |
72 hours |
2.5 hours |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Some potential for abuse
Has a low potential for abuse relative to those in schedule 3. It has a currently accepted medical use in treatment in the United States. Abuse may lead to limited physical dependence or psychological dependence relative to those in schedule 3. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 375 drugs are known to interact with Carisoprodol:
|
A total of 453 drugs are known to interact with Cyclobenzaprine:
|
A total of 653 drugs are known to interact with Tizanidine:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
April 09, 1959 |
August 26, 1977 |
November 27, 1996 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.